Terns: The fight against obesity continues with another catalytic programme for the first quarter of 2025 (TERN)

This article was written by

Terry Chrisomalis is a private investor in the biotechnology sector with years of experience using his applied science background to generate long-term value in healthcare.

He is the author of the Biotech Analysis Central investment group, which contains a library of over 600 biotech investing articles, a model portfolio of over 10 small- and mid-cap stocks with in-depth analysis of each, live chat, and a variety of analysis and news reports to help healthcare investors make informed decisions.

Analyst Disclosure: I/we do not have any stock, option or similar derivative positions in any of the companies mentioned, and we have no plans to initiate any such positions in the next 72 hours. This article was written by me and expresses my own opinions. I receive no compensation for it (except from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's revelation: Past performance is no guarantee of future results. No recommendation or advice is offered as to whether an investment is suitable for a particular investor. The opinions or views expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a broker-dealer, a broker-dealer, or a licensed investment advisor or investment bank in the U.S. Our analysts are third-party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Source link

Leave a Comment